An Open-Label, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced NSCLC and Other Solid Tumors
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Pembrolizumab (Primary) ; Porustobart (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Harbour BioMed
- 09 Aug 2022 Results (Part 1; n=12; As of 20 Dec 2021) assessing the safety, anti-tumor activity, PK/PD and RP2D of HBM4003 in combination with pembrolizumab, presented at the 2022 World Conference on Lung Cancer.
- 17 Jun 2021 According to Harbour BioMed media release, first patient has been dosed in this study.
- 17 Jun 2021 Status changed from not yet recruiting to recruiting, according to Harbour BioMed media release.